PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Automated Insulin Delivery Improves Glycemia, Not Yet Perinatal Outcomes

★ Editor's Pickautomated insulin deliveryhybrid closed-loopCamAPS FXMiniMed 780GTandem Control-IQtype 1 diabetespregnancycontinuous glucose monitoringtime in rangeintegrative reviewhealth equityAiDAPTCRISTALCIRCUIT Women's Health / Reproductive

Background Information

Automated insulin delivery transforms diabetes management in pregnancy.

Automated insulin delivery (AID) systems have significant potential to improve glycemic control during pregnancy in individuals with type 1 diabetes, enhancing maternal and neonatal health outcomes. The review highlights system-specific evidence for improved continuous glucose monitoring outcomes with AID systems like CamAPS FX and MiniMed 780G, but notes gaps in long-term maternal and neonatal data. The study underscores the need for equitable implementation of AID systems, considering algorithm design, user interaction, and access to specialist care, while acknowledging existing evidence limitations. AID systems can significantly enhance pregnancy outcomes in type 1 diabetes, but require careful socio-technical assessment for equitable use.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Li J, Qi TN, Tan X, Jayasekara R

Citation: Li J, Qi TN, Tan X, et al. Automated Insulin Delivery in Pregnancy With Type 1 Diabetes: An Integrative Review of Clinical Evidence, Socio-Technical Implementation and Equity. Journal of diabetes research. 2026;2026(1):e1989683. doi:10.1155/jdr/1989683

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.